Business
Stockhouse investors who are dialed into the not-only nascent but now, pardon the pun, mushrooming psychedelics sector are likely familiar with a mental health and wellness company “centred on developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies.” In short, an entirely new way of successfully addressing and treating the growing prevalence of mental health issues and desire for greater wellness as a whole. Numinus Wellness Inc. (NUMI) (TSX-V.NUMI, OTCMKTS: LKYSF, Forum) is a Company that is “creating an ecosystem of health solutions” aimed at advancing psychedelic laboratory testing, therapy, and research delivering psychedelic-assisted psychotherapies and other transformative and supportive health solutions. Also known as ‘magic mushrooms’, psilocybin and its assisted psychotherapy are currently being studied as a treatment for a wide range of mental health conditions including depression, anxiety, and substance use disorders. The Company says its vertically-integrated ecosystem positions it to be a first-in-market, trusted leader in the delivery of psychedelic-assisted psychotherapies when regulated. From product development and supply, to analytics and testing, to clinical protocol development and implementation science in partnership with leading research organizations, the unique ecosystem approach allows Numinus to ensure quality control and best-in-class delivery with steady revenue streams to support its developments. In this lively and informative podcast, Stockhouse Media’s Dave Jackson reached out the Company Chairman & CEO Payton Nyquvest to discuss a myriad of timely and intriguing topics that investors need to know about this burgeoning market.